Briefly noted: L Waters et al. Annals Int Med 2020; doi:10.7326/L20-0497. Celiac Disease Remission With Tofacitinib
The authors describe a male with a well-documented case of celiac disease and alopecia areata. He was placed on tofacitinib off-label for his alopecia areata and it was discovered that his celiac disease had developed “complete histologic and serologic remission…while he was still on a gluten-containing diet.” Prior to medication, he had confirmation of both severe histologic changes and high tTG IgA titers.
The authors note that tofacitinib inhibits CD8+ T-cell mediated enteropathy in a transgenic mouse model.
My take (borrowed from authors): Tofacitinib has many potential adverse effects but may considered for further study, especially in refractory celiac disease.
Pingback: Oral Treatment of Celiac Disease & Research Optimist | gutsandgrowth
Pingback: Engineering New Treatments for Celiac Disease | gutsandgrowth